Molecular analysis of the SGLT2 gene in patients with renal glucosuria - Wikidata - wikimedia - TriplyDB

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

http://www.wikidata.org/entity/Q28211392

about

sameAs

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus Dapagliflozin for type 2 diabetes mellitus Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes Microarray gene expression profiling and analysis in renal cell carcinoma Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Mutation of solute carrier SLC16A12 associates with a syndrome combining juvenile cataract with microcornea and renal glucosuria Active sugar transport in health and disease Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion The Na(+)/glucose cotransporters: from genes to therapy Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.SGLT2 mediates glucose reabsorption in the early proximal tubule.The Sweet Pee model for Sglt2 mutation SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.Empagliflozin in the treatment of type 2 diabetes: evidence to date Hypouricaemia and hyperuricosuria in familial renal glucosuria.Mutation in the Monocarboxylate Transporter 12 Gene Affects Guanidinoacetate Excretion but Does Not Cause Glucosuria Structural selectivity of human SGLT inhibitors.Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report.Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus Novel SLC5A2 mutation contributes to familial renal glucosuria: Abnormal expression in renal tissues.Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes.A recurrent deletion in the SLC5A2 gene including the intron 7 branch site responsible for familial renal glucosuria.Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus Dapagliflozin: where does it fit in the treatment of type 2 diabetes?A Case of Isolated Glycosuria Mediated by an SLC5A2 Gene Mutation and Characterized by Postprandial Heavy Glycosuria Without Salt Wasting Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.

P2860

Q21195757-51ED0196-DF7B-47A4-9F1A-1ACFC703247D Q24234557-85375E2D-0021-45A3-871F-74B0F04567BE Q24684670-5E5FDCBB-D77C-4C68-910D-A85A01E77A52 Q24799432-AA57CFB2-AC5E-428A-B406-EC2B225530E9 Q28072765-81B6D4D6-49E8-43FC-863D-0DA7AD9F93D1 Q28270419-54443582-04E3-4377-9BB5-BDD9653E7BBD Q28283298-05400669-0F1D-4033-9019-87C178884C8F Q28286955-7BB65820-6143-4B20-A0C8-DB2ECB9A4BAA Q28297657-3831582F-759D-4828-BC35-0630EB0F1B9C Q28552106-A91FA88C-CF15-4A87-8DEA-A1DC83F95CA5 Q30429061-2C7F5098-AE9A-4032-87A7-63A2C390665A Q30833760-BDC16622-6933-46B8-8C17-B9049334AF3C Q33759610-E7BD48FD-8FCA-4214-AA69-42F985D1F66C Q34120717-3E2EE562-15D9-44D4-BC86-D4D4B373D8ED Q34198692-A6FA816F-5243-4A5F-8DE0-55AB91B0FDDC Q34315521-69CBE88A-021C-4D6D-9471-138BA60B9EF6 Q34453811-BAD11518-EDB0-4C7F-9269-4C49DBA9B607 Q34457264-3F1FFCA0-C800-4A59-A674-AF68456EC371 Q34457273-98078551-A56F-48C4-AF3C-019CCD4F54DD Q34460468-C1E7DC7B-731D-4BDB-BE64-F17DFEFF3984 Q34501684-41DA0F33-2D9A-46F1-A979-9EE56278A6DA Q34502358-0E71B04B-B018-4048-8D23-ACA68DDEB19F Q35626570-9F32AE49-913D-435F-BC29-301F1DA988D2 Q35777605-058D6D98-BE7D-4605-965B-44CF161301BE Q35895528-78519C41-897A-4844-9256-86EB5A6CFAC4 Q35965090-C04B1524-5435-4C8A-B61C-5D777B6CF8D5 Q36221586-A4438200-0F19-43B5-B615-0AD6922B7019 Q36592820-74929868-3420-415B-A166-5330E6BE8DEE Q37106990-E467FC24-FF14-486B-B323-18356B1CC908 Q37139427-AEA221DE-435C-49D7-B7BB-B00FCBCE6C5A Q37175717-E95A7B92-C7D1-47A1-A9D3-9CF7255BA349 Q37244327-C3B5056D-76AE-44E6-ACA2-EE76B2DF623C Q37282415-0D5569C2-27FA-485D-9E15-69FD6AAEA21E Q37468412-4D70D62C-DB3D-44B5-A230-D27148355F66 Q37593086-47051CF4-6631-4439-AAD0-9BF429C28736 Q37681068-8F4B5E1F-FF14-4321-8F98-B332BE51B021 Q37810292-CCD4A80F-90AC-43D3-A0B4-60FED664A37A Q37872125-FF336C3A-2AD5-4128-9725-D60CAEDBEFDD Q37990891-B5B1E8C5-50A8-4495-9507-8F40081CC913 Q38018930-263D04D2-39D7-4838-9C61-7E52DF43A45B

P2860

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

http://www.wikidata.org/entity/Q28211392

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@ast

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@en

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@nl

type

label

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@ast

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@en

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@nl

prefLabel

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@ast

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@en

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@nl

P1433

Q28211392-1AFA9BE5-51F0-4875-81A3-0ED5F7A0F76D

P1476

Q28211392-0D5252F7-2AA0-44E1-8188-3F6B4045528B

P2093

Q28211392-3750599E-3057-40C1-B235-820ABE3E4200

Q28211392-3E4AB189-AFEC-430A-939B-1E6C3B1F80EA

Q28211392-4DB9C37C-06D9-4E49-A9C6-AD8410863BC3

Q28211392-587FFF0A-F99A-4344-97F2-412E97DDFD94

Q28211392-658FA037-2454-450B-81F7-D706D470D2FF

Q28211392-755497E7-58C5-4A0E-B562-994D60982F23

Q28211392-8F7F3CC3-6871-4A59-AD49-260CBDAF7D16

Q28211392-907A15EA-B21C-4780-99D9-A42E85AC610E

Q28211392-A93374C9-B610-455C-9DDC-31DAEFFADA78

Q28211392-B5001AE0-416F-4AD4-B91D-0CE961372AC9

P304

Q28211392-E6CF60D1-5D3A-492E-8276-16AFA14E5C97

P31

Q28211392-09BBD370-29D7-4D72-9920-DD2356677690

P3181

Q28211392-2F43B97D-2698-4FD5-868B-83775FCC3C33

P356

Q28211392-8587D407-E791-4A16-B8FD-A5B20BAC9EEF

P407

Q28211392-294C51A5-264A-4BE8-ACEF-B0580719070A

P433

Q28211392-C90DCBF8-3EF4-419B-996B-CFCE3002CD01

P478

Q28211392-A25A5BFA-F0B9-4FD4-A4BA-980DA0DDAB89

P50

Q28211392-1F4F9BC6-504D-4508-9F34-BDDFB5E9367D

Q28211392-86098E78-BF5A-4F75-9C4D-A4657FF65202

Q28211392-FEE92F6B-6A03-445B-BB70-F027E124C530

P577

Q28211392-DD1BC65E-66BD-4356-A40F-692CF3095CEF

P5875

Q28211392-65496A59-D90C-4175-AAF7-0EA0D95B29E2

P698

Q28211392-C6E460A0-1850-4301-AC7C-0FBF4DDE12E6

P921

Q28211392-12642FE0-0523-4CD4-9B93-8948394E36BB

P3181

P356

01.ASN.0000092790.89332.D2

P1433

Journal of the American Society of Nephrology

P1476

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

@en

P2093

Christoph L Lassen

http://www.w3.org/2001/XMLSchema#string

Dan Klaerke

http://www.w3.org/2001/XMLSchema#string

Jochen H H Ehrich

http://www.w3.org/2001/XMLSchema#string

Jürgen Schaub

http://www.w3.org/2001/XMLSchema#string

Markus Daschner

http://www.w3.org/2001/XMLSchema#string

Markus Kemper

http://www.w3.org/2001/XMLSchema#string

Martin Bald

http://www.w3.org/2001/XMLSchema#string

Martina Kinner

http://www.w3.org/2001/XMLSchema#string

Paul Eggert

http://www.w3.org/2001/XMLSchema#string

Peter G F Swift

http://www.w3.org/2001/XMLSchema#string

P304

2873-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1358591

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/01.ASN.0000092790.89332.D2

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Reinhard Schneppenheim

Johannes Brodehl

Flemming Skovby

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231584428

http://www.w3.org/2001/XMLSchema#string

P698

14569097

http://www.w3.org/2001/XMLSchema#string

P921